Business Wire

CA-USERTESTING,-INC.

24.3.2021 14:02:16 CET | Business Wire | Press release

Share
UserTesting’s Eighth Annual CX Survey Reveals That Customer Empathy Is No Longer Optional

UserTesting , a leading provider of on-demand human insights , today released new data identifying how the pandemic has put customer experience (CX) and empathy center stage. Findings show that businesses are in one of two categories, those doubling down on CX and those scaling back on it, and that customer feedback collection is on the rise, with 72 percent of organizations stating that they plan to increase their investments in 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005313/en/

The vast majority, 71 percent , noted that they’re either in-process or have completed their digital transformation. This is a sharp increase from 2019 survey results, in which only 56 percent said they were that far along in their journey. This indicates that the pandemic has helped to motivate teams to dedicate more time and resources to digital transformation to improve overall CX.

The 2021 CX Industry Report uncovered three key trends influencing customer experience today:

  • Feedback has gone remote
    The remote-centric business environment brought about by the pandemic is, for many, here to stay. A remote-first approach to customer feedback is a new strategy that many companies will continue to embrace into the new normal, and for good reason. The survey revealed that moving to online user research can cut costs by an average of 40 percent . The impact on a company’s bottom line is also significant. Moving to online user research was found to increase revenue by about 40 percent . Many survey respondents noted that the pandemic will permanently reduce the amount of in-person research they do moving forward.
  • The pandemic has put the focus on CX
    Although consumers’ interactions with brands have changed, expectations have never been higher. The survey found that companies acknowledge an increase in the use of customer feedback, which drove more investments into customer feedback and user research. Both trends are likely to continue. Despite the efforts to improve CX, many survey respondents noted their companies are still in the early stages of establishing their CX practices with 60 percent admitting that their organization doesn’t have a formal CX strategy in place or only reacts to issues as they happen.
  • Teams are doing more with less
    Time and resources were significantly impacted by the pandemic which, in many cases, meant more work with fewer resources. Nearly 70 percent of those surveyed reported reductions in spending or workforce resources due to business changes caused by the pandemic. Fewer resources impacted nearly half of those surveyed with 53 percent reporting an increase in workload. The pandemic also required many companies to quickly pivot their product or service offerings. Forty-six percent of respondents reported a change to their product roadmap due to the pandemic.

“We have been through a year unlike any other where organizations have had to adapt to changing customer needs. The past year has shown that organizations must prioritize customer understanding and empathy to build long term customer loyalty,” said Janelle Estes, Chief Insights Officer at UserTesting. “The takeaway for every size organization should be that talking with and listening to your customers cannot take place only during times of crisis but should be part of regular business practices.”

To access the full UserTesting 2021 CX Industry Report, click here .

Methodology and survey results

In this eighth annual Customer Experience Industry Survey, we asked over 4,700 professionals from around the world across a wide variety of industries how their organizations are approaching customer experience and conducting CX research.

About UserTesting

UserTesting enables every organization to deliver the best customer experience powered by human insight. With UserTesting’s on-demand Human Insight Platform , companies across industries make accurate customer-first decisions at every level, at the speed business demands. With UserTesting, product teams, marketers, digital, and customer experience executives, designers and UX researchers confidently and quickly create the right experiences for all target audiences, increasing brand loyalty and revenue. UserTesting customers include more than half of the world’s top brands. UserTesting is headquartered in San Francisco, CA. To learn more, visit www.usertesting.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye